Care Today, Cure Tomorrow

We would like to thank the SCD community for joining MSCDA in Baltimore as we shared information on the latest medical developments and provided useful educational materials in an effort to spread awareness and improve the lives of those living with sickle cell disease.

“Care Today, Cure Tomorrow,” joined patients, families, and providers to discuss and share information that addressed the critical issues framing the future of Sickle Cell Disease treatment and management.

Date And Time

Sat, May 18, 2019

9:00 AM – 4:00 PM EDT

Conference Presentations

Agenda

Location

Sheraton Inner Harbor

300 South Charles Street

Baltimore, MD 21201

Share this post

CONTACT US
KEEP IN TOUCH
Sign up for our email list, or follow us on social media, to stay in-the-know about the Maryland Sickle Cell Disease Association
Scroll to Top

Breaking News

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

On December 8, 2023, “The U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling an innovative advancement in the field of gene therapy."